Mochi Health and Livelong Women’s Health Summit Partner to Advance Women’s Metabolic Health

Key Takeaways

• Mochi sponsors Livelong Summit, showcasing women's health focus
• CEO Myra Ahmad leads GLP‑1 women’s panel discussion
• Platform now covers 120+ conditions, beyond weight loss
• Over 500,000 patients served across all 50 states
• Emphasis on transparent, affordable telehealth marketplace

Summary

Mochi Health announced its role as a Premiere Sponsor of the Livelong Women’s Health Summit, scheduled for April 17‑18 in San Francisco. Founder and CEO Myra Ahmad, M.D., will headline a session on GLP‑1 medications and host a roundtable on women’s hormonal health. The participation underscores Mochi’s expansion from GLP‑1 weight‑management into a broader telehealth marketplace covering more than 120 conditions. To date, the platform has served over 500,000 patients across all 50 states.

Pulse Analysis

The rise of GLP‑1 therapies has reshaped the conversation around obesity and metabolic disease, yet women’s unique hormonal profiles demand nuanced guidance. Industry conferences like the Livelong Women’s Health Summit provide a rare forum where clinicians, researchers, and innovators can dissect efficacy, safety, and long‑term outcomes specific to female patients. By dedicating a session to the "Ozempic Era," the summit acknowledges that women are both major beneficiaries and a distinct demographic requiring tailored treatment pathways.

Mochi Health leverages its three‑sided marketplace to meet this need, offering patients the freedom to select providers, pharmacies, and personalized treatment plans. Since its 2022 launch, the company has broadened its catalog from GLP‑1 weight‑loss solutions to encompass skincare, hair loss, mental health, and reproductive services, now supporting more than 120 conditions. Serving half‑a‑million users nationwide, Mochi’s model emphasizes price transparency and eliminates traditional middlemen, which resonates with cost‑conscious consumers and providers seeking streamlined workflows.

For investors and the broader telehealth ecosystem, Mochi’s summit involvement signals a strategic push into women‑focused metabolic care—a segment projected to outpace general weight‑management growth in the next five years. The combination of high‑visibility thought leadership and a scalable, condition‑agnostic platform positions Mochi to capture market share as insurers and employers prioritize comprehensive, gender‑responsive health solutions. Continued expansion could accelerate adoption of GLP‑1 therapies while reinforcing the value of integrated, patient‑centric digital health ecosystems.